July 22 Could Ignite a Financial Nightmare

He said “a major reckoning is coming” 3 months before 2025’s crash… his work pointed to the Covid crash 25 days before stocks bottomed… and his firm spends $8 million a year in search of the biggest declines in the stock market. Now – one man has a chilling warning for the financial system on July 22.

Tue, July 22 at 10:00AM ET
 
 
 
 
Register Here

Hot Stocks

The stock market changes from minute to minute, and what’s hot today may not be hot tomorrow. Our expert analysts spot hot stocks that are heating up before the crowd swoops in to bid prices higher, and our journalists sift through the noise to shine a light on trending investments -- in spaces ranging from quantum computing to marijuana stocks -- to determine whether they’re actually worth your time.

KemPharm Stock Is Having a Hard Time After Its Recent Runup

By Mark R. Hake, CFA
KemPharm has a new ADHD drug, but after a recent short-squeeze KMPH stock is likely to fall without further financing.

Foley Trasimene Acquisition Corp Is a Modern Wall Street Creation

By GS Early
This BFT stock SPAC certainly has Wall Street credibility, but the lingering question is how complicated do these investments need to be?

A 60% Plunge Doesn’t Make Churchill Capital IV Stock Cheap

By InvestorPlace Research Staff
Investors clearly misread CCIV stock ahead of its announced merger with Lucid. In that context, the recent sell-off simply makes sense.

7 Beaten Down Stocks With Insider Buying

By Mark Putrino, CMT
These seven stocks have been beaten down. But insiders think the selling was overdone. There has been significant insider buying.

Zomedica’s Pet Lab Product Launch Will Push Its Value Higher

By Mark R. Hake, CFA
Zomedica’s product launch will push its value higher. ZOM stock is worth between $2.45 to $3.17 with a 10% share of the pet diagnostic lab market.

Hopefuls Need GameStop to Beat the Law of Diminishing Returns

By Josh Enomoto, InvestorPlace Contributor
On the eve of a critical earnings report for GME stock, here’s the playbook for how the next three months may look like.

GameStop Still Has More Questions Than Answers

By Chris Markoch, InvestorPlace Contributor
Ryan Cohen deserves time to execute his plan for GameStop. But that doesn’t mean you have to invest in GME stock while he does.

7 Education Stocks That Could Benefit from a Wealth Tax

By Josh Enomoto, InvestorPlace Contributor
With Democrats having a slim majority in Congress, now is the time to push an education tax which may force a rethink on stocks to buy related to academia.

Ocugen Looks Very Dicey at Current Levels

By Tom Taulli, InvestorPlace Contributor
Ocugen believes it can distribute 100 million doses of a Covid-19 vaccine in the U.S. But this looks like a long shot for OCGN stock.

Koss Corp Still Has Not Raised Capital at Its Elevated Stock Price

By Mark R. Hake, CFA
Koss Corp still has not raised capital at its elevated stock price. Koss stock would benefit from equity, convertible debt and/or preferred capital raise.

Ignore Last Month’s Noise, Alpha Pro Tech Stock Is Heading Lower

By InvestorPlace Research Staff
What lies ahead? Continued declines back to the single-digits. Perhaps not to its pre-pandemic prices. But still, well below what we see today. So, what's the verdict on APT stock? As was the case last year, stay away.

Why You Should Avoid Pfizer Stock Despite Its Covid-19 Vaccine

By InvestorPlace Research Staff
While Pfizer has a Covid-19 vaccine out for the public, PFE stock isn't getting much love from Wall Street. Let's avoid it for now.

Churchill Capital IPO, Saudi Ties Will Help Lucid Motors to Be Tesla 2.0

By Dana Blankenhorn, InvestorPlace Contributor
Lucid has set plans for recycling its batteries and getting to 500,000 cars in a year, competing head-to-head with Tesla and legacy car makers. CCIV cash will fuel that.

Second Sight Medical Products Is No Short Squeeze

By Josh Enomoto, InvestorPlace Contributor
EYES stock jumped higher off a very encouraging FDA approval but now is the time to apply a little more scrutiny to the Second Sight Medical investment.

Become a Unicorn Hunter with Pershing Square Tontine Holdings

By David Moadel, InvestorPlace Contributor
There's an aura of mystery surrounding PSTH stock, but that's okay as the company is led by a highly successful business mogul.

Roblox’s Network Effects Puts It Into a Field of Its Own

By Thomas Logue, CFA
Roblox's incredible network effects, robust user growth and the digital era make RBLX stock a prime candidate for long-term success.

Earnings Could Help Ideanomics Stock Recapture Investor Confidence

By Louis Navellier and the InvestorPlace Research Staff
IDEX stock has been faltering ever since the company announced it would no longer report monthly MEG unit delivery numbers.

Buy Snap Stock as the ‘Great Reopening’ Catalyst Begins

By Luke Lango, InvestorPlace Senior Investment Analyst
As more people travel, party, and socialize more in 2021/22, they're going to want to share those experiences more on Snapchat, so buy SNAP stock.

Avoid Sundial Stock As It’s Running on Reddit Hype

By InvestorPlace Research Staff
SNDL stock had a nice pop earlier this year, but the rally has been unsustainable since. We're avoiding Sundial for now in favor of others.
Load More Articles